Improving gastric balloons to treat obesity

Alexis Sudlow, Carel W le Roux

Research output: Contribution to journalComment/debatepeer-review

1 Citation (Scopus)
Original languageEnglish
Pages (from-to)1940-1941
Number of pages2
Issue number10315
Early online date15 Nov 2021
Publication statusPublished (in print/issue) - 27 Nov 2021

Bibliographical note

Funding Information:
CWlR reports grants from the Irish Research Council, Science Foundation Ireland, Anabio, and the Health Research Board. He serves on advisory boards of Novo Nordisk, Herbalife, GI Dynamics, Eli Lilly, Johnson & Johnson, Sanofi Aventis, AstraZeneca, Janssen, Bristol-Myers Squibb, and Boehringer Ingelheim, outside the area of work commented on here. He also has been since January, 2011, the chief medical officer and director of the Medical Device Division, and is a previous investor in Keyron, which develops endoscopically implantable medical devices intended to mimic the surgical procedures of sleeve gastrectomy and gastric bypass. He divested stock holdings in Keyron in September, 2021. AS declares no competing interests.


  • Body Weight
  • Gastric Balloon/adverse effects
  • Humans
  • Obesity/therapy

Cite this